China Resources Pharmaceutical Group (STU:640) ROCE %: 8.97% (As of Dec. 2025)


STU:640 China Resources Pharmaceutical Group Ltd STU:640
63 GF Score
Price €0.49
GF Value €0.64
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China Resources Pharmaceutical Group ROCE %?

China Resources Pharmaceutical Group STU:640 +2.97% 63 ROCE % is 8.97% as of Dec. 2025. GuruFocus rates STU:640 with a GF Score™ of 63/100 and a GF Value™ of €0.64 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China Resources Pharmaceutical Group's annualized ROCE % for the quarter that ended in Dec. 2025 was 8.97%.

China Resources Pharmaceutical Group  (STU:640) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China Resources Pharmaceutical Group ROCE % Related Terms

China Resources Pharmaceutical Group ROCE % Historical Data

* Premium members only.

The historical data trend for China Resources Pharmaceutical Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Resources Pharmaceutical Group ROCE % Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.85 11.77 11.61 11.21 9.89

China Resources Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.37 13.98 8.14 10.65 8.97
STU:640
63GF Score
China Resources Pharmaceutical Group Ltd STU:640
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Resources Pharmaceutical Group ROCE % Calculation

China Resources Pharmaceutical Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=1675.982/( ( (33810.088 - 17343.379) + (34655.092 - 17243.103) )/ 2 )
=1675.982/( (16466.709+17411.989)/ 2 )
=1675.982/16939.349
=9.89 %

China Resources Pharmaceutical Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=1552.044/( ( (34635.739 - 17426.688) + (34655.092 - 17243.103) )/ 2 )
=1552.044/( ( 17209.051 + 17411.989 )/ 2 )
=1552.044/17310.52
=8.97 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.97% mean?
China Resources Pharmaceutical Group (STU:640) has a ROCE % of 8.97% as of Dec. 2025.
Is China Resources Pharmaceutical Group's ROCE % too high?
China Resources Pharmaceutical Group's current ROCE % is 8.97%. The Drug Manufacturers industry median ROCE % is 7.03. China Resources Pharmaceutical Group's value of 8.97% is 27.6% above this industry median. Overall, China Resources Pharmaceutical Group has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's ROCE % compare to ZTS and UTHR?
China Resources Pharmaceutical Group's ROCE % of 8.97% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. China Resources Pharmaceutical Group's value of 8.97% is 27.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Pharmaceutical Group's current ROCE % of 8.97% is 27.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current ROCE % is 8.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group (STU:640) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.64, compared to a current price of €0.49 — trading 24.1% below its estimated fair value. The current ROCE % is 8.97% and 27.6% above the Drug Manufacturers industry median of 7.03. China Resources Pharmaceutical Group's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For China Resources Pharmaceutical Group (STU:640), the current ROCE % is 8.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Resources Pharmaceutical Group (STU:640) Overvalued in 2026?

Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.49 is trading 24.1% below its estimated GF Value™ of €0.64. GuruFocus considers China Resources Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for STU:640:

  • ROCE %: 8.97%
  • GF Value™: €0.64 vs. price of €0.49 (24.1% below fair value)
  • GF Score™: 63/100 with 3 warning signs
  • Industry Position: 27.6% above the Drug Manufacturers median

No single metric tells the full story. See the STU:640 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Resources Pharmaceutical Group Business Description

Other Exchanges 03320:Hong Kong
Address 26 Harbour Road, Room 4104-05, 41st Floor, China Resources Building, Wanchai, HKG
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
63GF Score

Get the complete analysis for STU:640

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.49
Price
€0.64
GF Value